With a likely Republican majority in the House and Senate and a Republican president, there may be a sense that the party has a mandate to lead initiatives and enact significant policy changes. Any end-of-year legislative package will be narrower than initially expected, but the ACR’s top priority remains addressing cuts to physician reimbursements.
ACR Endorses Woodcock for FDA Commissioner, Begins Relationship Building with New Administration Leaders
With the approval of its Board of Directors, the ACR sent a letter to President Biden and newly minted Secretary of Health & Human Services Xavier Becerra, strongly supporting Janet Woodcock, MD, to be nominated as the FDA’s permanent commissioner. The ACR also congratulated Secretary Becerra upon his confirmation.
After the 2020 Election, What’s in Store for Rheumatology Advocacy?
Despite high voter turnout and many new faces entering Congress, minimal power shifts in most levels of government will have implications for the ACR’s advocacy agenda in 2021.
Top ACR Priorities in 2017 Include Drug Costs, MACRA
With a new federal administration and Republican-controlled Congress taking the helm in 2017, the ACR Government Affairs Committee has identified top legislative and regulatory priorities for the year. “The main priority is going to be helping represent the rheumatology community as Medicare is reformed, because the era of MACRA started Jan. 1,” says Angus Worthing,…